X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VAS203 (ronopterin) significantly reduces lactate levels in brain microdialysate from TBI patients reflecting energetic stability and neuroprotection during the early vulnerable phase.
Lead Product(s): Ronopterin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: VAS203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2022
Details:
The NOSTRA trial (NO Synthase in TRAumatic Brain Injury) is a pivotal European trial assessing the efficacy and safety of Ronopterin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain (TBI) injury patients.
Lead Product(s): Ronopterin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: VAS203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
NOSTRA III is a 220 patient Phase III clinical trial assessing efficacy and safety of Ronopternin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain injuries.
Lead Product(s): Ronopterin
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: VAS203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
